This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety of a Purified Standardised Bee Venom Preparation

This study has been completed.
Information provided by (Responsible Party):
Allergopharma GmbH & Co. KG Identifier:
First received: December 9, 2005
Last updated: March 1, 2013
Last verified: March 2013
The trial is performed to assess efficacy and safety of a purified standardised bee venom preparation in bee venom allergy

Condition Intervention Phase
Bee Venom Allergy Biological: bee venom Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Immunotherapy of Bee Venom Allergy: Evaluation of a New Purified Bee Venom Preparation in Comparison With Already Published Studies.

Resource links provided by NLM:

Further study details as provided by Allergopharma GmbH & Co. KG:

Study Start Date: March 2003
Study Completion Date: April 2010
Primary Completion Date: January 2005 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • History of bee venom allergy,
  • Positive RAST for bee venom,
  • Positive skin prick test for bee venom

Exclusion Criteria:

  • Serious chronic diseases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00263952

Allergopharma GmbH & Co. KG
Reinbek, Germany, 21465
Sponsors and Collaborators
Allergopharma GmbH & Co. KG
Principal Investigator: Annemie Narkus, M.D.
  More Information

Additional Information:
Responsible Party: Allergopharma GmbH & Co. KG Identifier: NCT00263952     History of Changes
Other Study ID Numbers: Al0202ig
Study First Received: December 9, 2005
Last Updated: March 1, 2013

Keywords provided by Allergopharma GmbH & Co. KG:
Bee venom allergy
Specific immunotherapy

Additional relevant MeSH terms:
Immune System Diseases processed this record on September 20, 2017